The PennZone

  • Home
  • Non-profit
  • Music
  • Marketing
  • Entertainment
  • Books
  • Health
  • Business
  • Automotive

Utah attempts to legalize placenta cell therapy
The PennZone/10266985

Trending...
  • LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports
  • Jacombs Tickets Partners with UEFA to Offer Champions League Tickets
  • Everything Policy Unveils Their Classroom Resources Behind Every Policy Topic
Parent's Guide to Cord Blood Foundation
Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

BROOKEVILLE, Md. - PennZone -- Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

Parent's Guide to Cord Blood Foundation is a small non-profit in the biotech space. We are the first to break the story that the Utah state legislature did not realize what they were voting for when they passed Utah S.B. 199.

More on The PennZone
  • Renew Integrative Health Publishes Updated Peptide Therapy Guide to Help Patients Understand Their Options
  • Lehigh County Drug and Alcohol Celebrates Grand Opening of Journeys
  • Timbrana Addresses the Missing Follow-Through in Commercial Construction Projects
  • AI Agents Are Getting Their Own Computers. HRTech Leading in Vertical Harness Development
  • UK Financial Ltd Announces Two-for-One Upgrade of Maya 3 to Maya 3G Token Using Chainlink Cross-Chain Technology

The FDA still considers unapproved stem cell therapies to be illegal, and when it comes to drug regulations, federal law takes supremacy. This is not the same as states ignoring federal law and legalizing recreational drugs. In the case of stem cell therapy, patients that receive unregulated products with insufficient oversight could suffer serious adverse events. The new law Utah S.B. 199 is going to trigger a showdown between the federal government and Utah. Doctors who administer therapy to patients under the new Utah law could be sued by the Dept. of Justice. At a bare minimum, we are calling for the state of Utah to establish oversight of this arena before patients are hurt.

Contact
Frances Verter, PhD
***@parentsguidecordblood.org


Source: Parent's Guide to Cord Blood Foundation

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • AutoProIT Achieves Cyber Essentials Certification, Reinforcing Its Commitment to Secure Digital Transformation
  • DayPass llega a ChatGPT y Claude
  • DayPass launches in ChatGPT and Claude
  • Renkeer Water Quality Sensors Support Efficient Operation of AI Liquid Cooling Systems
  • Victor Archibong Expands ItsArchiDuh Creator Brand
  • Talented Learning Unveils 2026 LMS Award Winners
  • Pittsburgh Digital Marketing Agency Moves to Babcock Boulevard in the North Hills
  • ClearSight Therapeutics Receives U.S. Patent Notice of Allowance
  • Revinate launches hospitality's first data activation platform
  • HLN Consulting Names Lilly Kan as Its First Chief Executive Officer
  • BitTitan Accelerates Large-Scale Document Migrations with MigrationWiz
  • Clearnetworx Deploys netElastic vBNG, CGNAT And netVision To Power Fiber Expansion Across Colorado's Western Slope
  • Glenn Strange - Iconic Horror actor of Universal Studios Frankenstein's Monster Fame Honored
  • Creole101 Launches Multilingual Dictionary App with 50,000+ Entries, Vocabulary Games and Haitian Cultural Resources
  • Hilton Waikiki Beach Resort & Spa Introduces Level 37 Sky Lounge by Casamigos
  • Self-Published Dad's Santa Book Finally Found After 3 Years on Amazon
  • Meta Partnership Expanding as Omni One Orders Surge 3X -New Consumer Bundles, Defense Opportunities & AI Robotics: Virtuix Holdings: N A S D A Q: VTIX
  • Roots for Boots to Participate in 2026 Adams County Community Foundation Giving Spree
  • Timbrana Helps General Contractors Improve Jobsite Visibility and Subcontractor Accountability
  • Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1

Popular on PennZone

  • Dion Abadi Publishes Free Collector Tips Hub for Art and Jewelry Buyers - 120
  • UVIFY Brings Advanced Autonomous Systems Research to IROS 2026 in Pittsburgh
  • Subject matter experts: Present your ideas at IISE Annual Conference 2027 in Louisville
  • New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
  • Can Government Operate Better Through Innovation?
  • Her Song Lives On: Remembering Mrs. Darlene Davis Porter
  • Curtis Salgado shares a love letter to the city of Chicago and Otis Rush with new single
  • Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
  • World-Renowned Body Language Expert Mark Bowden Headlines INSPIRE Northwest 2026 in Wenatchee, WA
  • Keystone Consulting Engineers Expands into Brodheadsville, Strengthening Regional Engineering

Similar on PennZone

  • Critical FDA Milestone much Closer as Preservative-Free Ketamine Review Advances: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • ClearSight Therapeutics Receives U.S. Patent Notice of Allowance
  • Danish company biosuite introduces biotech procurement software to track outsourced R&D commitments
  • $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
  • Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
  • Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
  • Thar Process Partners with French Leader ExtrateX to Bring Prep to Process-Scale SFC to Europe
  • Biophysical Therapeutics brings longevity science to skincare with its new IF1 brand
  • ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us